Product Description
GW273225 is in development for epilepsy and bipolar disorder and can affect women of child bearing potential.
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Epilepsy
Phase 1: Bipolar Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NEC107110 | P1 |
Terminated |
Bipolar Disorder |
2007-11-16 |
2019-03-21 |
Treatments |
|
| NAP109169 | P1 |
Completed |
Bipolar Disorder |
2007-10-11 |
2019-03-21 |
||
| NEC107055 | P2 |
Withdrawn |
Epilepsy |
2008-03-01 |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|